Information  X 
Enter a valid email address

Syncona posts 33% jump in performance; to invest at top of guidance range

By BFN News | 07:39 AM | Wednesday 21 November, 2018

Life sciences investor Syncona said it had boosted its first-half net asset value per share by 33%, as its portfolio of companies generated higher returns. Net assets at 30 September were worth £1.39bn, or 208.1p per share. The company said it had invested £94.3m during the half year and expected investment for the full year to be at the top end of guidance of £75m-to-£150m. Syncona's portfolio includes imaging company Blue Earth Diagnostics, immunotherapy company Autolus and blindness-focused gene-therapy group Nightstar. 'Our differentiated model of founding, building and funding businesses has continued to gain momentum across the business in the first half,' chief executive Martin Murphy said. 'We have delivered excellent financial and operational performance, which has translated into strong NAV progression.' 'We have a high-quality portfolio of companies, a leading position in cell and gene therapy, and a strategic pool of capital, which underpins our ability to continue to build global leaders in life science.' Story provided by

a d v e r t i s e m e n t